Page 1 of 2
12

2025 (1 POST)

Karamertzanis PG, Rasenberg M, Shah I, Patlewicz G. 2025. Modelling in vitro mutagenicity using multi-task deep learning and REACH data. Chem Res Toxicol 38(8):1382-1407; doi: 19.1021/acs.chemrestox.5c00152. PMID: 40680271.

View Abstract

2024 (4 POSTS)

Rudisill C, Jacobs M, Roy M, Brown L, Eaton R, Malloy T, Davies H, Tickner JT. 2024. The use of alternatives assessment in chemicals management policies: Needs for greater impact. Integr Environ Assess Manag 20(4):1035-1045; doi: 10.1002/ieam.4826. PMID: 37658263.

View Abstract

Mathisen GH, Bearth A, Jones LB, Hoffmann S, Vist GE, Ames HM,… Wikoff D, Wright F, Whaley P. 2024. Editorial: Time for CHANGE: System-level interventions for bringing forward the date of effective use of NAMs in regulatory toxicology. Arch Toxicol 98(8):2299-2308; doi: 10.1007/s00204-024-03802-6. PMID: 38877155.

View Abstract

Patlewicz G, Karamertzanis P, Paul-Friedman K, Sannicola M, Shah I. 2024. A systematic analysis of read-across within REACH registration dossiers. Comput Toxicol 30(June):100304; doi: 10.1016/j.comtox.2024.100304. PMID: 38993812.

View Abstract

Karamertzanis P, Patlewicz G, Sannicola M, Paul-Friedman K, Shah I. 2024. Systematic approaches for the encoding of chemical groups: A case study. Chem Res Toxicol 37(4):600-619; doi: 10.1021/acs.chemrestox.3c00411. PMID: 38498310.

View Abstract

2023 (1 POST)

Thompson CM, Proctor DM, Harris MA. 2023. Letter to “Chepelev et al. Establishing a quantitative framework for regulatory interpretation of genetic toxicity dose–response data: Margin of exposure case study of 48 compounds with both in vivo mutagenicity and carcinogenicity dose–response data.” Environ Mol Mutagen 64(4):259–260; doi: 10.1002/em.22537. PMID: 36916184.

2021 (2 POSTS)

Kimzey A, Mease K, Mounho-Zamora B, Wood M. 2021. 13. Biosimilar products—A review of past and current regulatory approval standards for preclinical safety studies. In: Translational Medicine: Optimising Preclinical Safety Evaluation of Biopharmaceuticals. CRC Press: Boca Raton, FL.

View Abstract

Choksi NY, Daniel AB, Allen DG, Clippinger AJ, Kleinstreuer NC. 2021. Prospective and retrospective evaluation of the eye irritation potential of agrochemical formulations. Research Triangle Park, NC: National Toxicology Program. NICEATM Report 01.

View Abstract

2020 (1 POST)

Brinkman AM, Klaren WD, Feifarek DJ, Hillwalker W, Jones F, Zorn KM, Ekins S. Use of a weighted scheme for the interpretation and contextualization of in vitro and in silico-derived estrogenic endpoints. Society of Toxicology 59th Annual Meeting, Virtual, 2020.

View Abstract

2019 (4 POSTS)

Thompson CM. The useful chemistry of perfluorinated compounds: Managing safety. The sticky subject of non-stick: Regulatory science challenges of per- and poly-fluorinated compounds (PFAS). Texas A&M University Interdisciplinary Faculty of Toxicology Training Program, 2019 Annual Regulatory Science Symposium, August 2019.

Proctor D. Use of the latest science in cancer risk assessment for hexavalent chromium: Is it time to step away from the default regulatory approaches? Invited presentation to the International Union of Toxicology (IUTOX) / International Congress of Toxicology (ICT) meeting, Honolulu, HI, June 2019.

Choksi NY, Truax J, Layton A, Matheson J, Mattie D, Varney T, et al. 2019. United States regulatory requirements for skin and eye irritation testing. Cutan Ocul Toxicol 38(2):141–155; doi: 10.1080/15569527.2018.1540494. PMID: 30418044.

View Abstract

Mihalchik-Burhans AL, Sullivan DW. 2019. Bridging issues of route. In: Gad S (ed), Integrated Safety and Risk Assessment for Medical Devices and Combination Products, pp. 273–297. Springer.

View Abstract

2018 (7 POSTS)

Casey WM, Chang X, Allen DG, Ceger PC, Choksi NY, Hsieh JH, et al. 2018. Evaluation and optimization of pharmacokinetic models for in vitro to in vivo extrapolation of estrogenic activity for environmental chemicals. Environ Health Perspect 126(9):97001; doi: 10.1289/EHP1655.

View Abstract

Wikoff D. Moving beyond theory to the use of systematic review to support regulatory decision making for evidence-based risk assessment. Society of Toxicology 57th Annual Meeting, San Antonio, TX, March 2018.

View Abstract

Proctor DM. Updating the regulatory risk assessment for hexavalent chromium in California: Implications for regulatory standards. Association of Environmental Health Sciences San Diego, CA, March 2018.

Clippinger A, Allen D, Jarabek AM, Corvaro M, Gaça M, Gehen S, Hotchkiss JA, Patlewicz G, et al. 2018. Alternative approaches for acute inhalation toxicity testing to address global regulatory and non-regulatory data requirements: An international workshop report. Toxicol In Vitro 48(April):53-70; doi: 10.1016/j.tiv.2017.12.011. PMID: 29277654.

View Abstract

Klaren WD, Grimm FA, Shen H, Rusyn I. In vitro approaches to grouping of complex substances and UVCBs: A case study of olefin streams. Society of Toxicology 57th Annual Meeting, San Antonio, TX, 2018.

View Abstract

Drechsel DA, Barlow CA, Bare JL, Jacobs NF, Henshaw JL. 2018. Historical evolution of regulatory standards for occupational and consumer exposures to industrial talc. Regul Toxicol Pharmacol 92(Feb):251–267; doi: 10.1016/j.yrtph.2017.12.005.

View Abstract

Butler L, Guzzie-Peck P, Hartke J, Bogdanffy M, Will Y, Diaz D, Mortimer-Cassen E,.., Greene N, et al. Revised draft EMA guidance on early clinical trials: Potential impacts and industry response. Abstract P204, American College of Toxicology 2017 Annual Meeting, Palm Springs, CA, 2017. Int J Toxicol 37(1):75-76; doi: 10.1177/10915818177494, 2018.

View Abstract
Page 1 of 2
12